milestone payments

Kowa Secures Expanded Rights to Nicox’s Glaucoma Drug NCX 470 in Major Global Deal

6 days ago talkbio0Tagged Clinical Trials, Denali, Glaucoma, Kowa, licensing agreement, milestone payments, naproxen-n-butyl nitrate, Ophthalmology specialty, royalties, TLX2 gene

Kowa; Nicox; NCX 470; glaucoma; exclusive rights; licensing agreement; Denali clinical trial; ophthalmology; royalties; milestone payments

Otsuka Inks $613M Deal for Cantargia’s Autoimmune Antibodies

1 week ago talkbio0Tagged Autoimmune Diseases, CAN10, Cantargia, global commercialization, Hidradenitis Suppurativa, IL1RAP antibodies, milestone payments, Otsuka Pharmaceutical, Systemic Scleroderma

Otsuka Pharmaceutical; Cantargia; autoimmune diseases; IL1RAP antibodies; CAN10; biotech deal; hidradenitis suppurativa; systemic sclerosis; milestone payments; global commercialization

Revolution Medicines and Iambic Announce $25M AI-Powered Drug Discovery Collaboration

2 weeks ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, Collaboration, Drug Discovery, Drug Industry, Iambic Therapeutics, milestone payments, Neoplasms, NeuralPLexer, propane, RAS-addicted cancers, Revolution Medicines

Revolution Medicines; Iambic Therapeutics; AI drug discovery; NeuralPLexer; PropANE; oncology; RAS-addicted cancers; collaboration; pharmaceutical industry; milestone payments

AstraZeneca Signs $110M AI-Driven R&D Deal with CSPC Pharmaceutical for Chronic Disease Drugs

1 month ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, AstraZeneca, China pharma, Chronic disease, Collaboration, Dosage Forms, Drug Discovery, Drug Industry, GZMH gene, Immune System Diseases, milestone payments, oral therapies

AstraZeneca; CSPC Pharmaceutical; AI drug discovery; chronic diseases; immunological diseases; oral therapies; R&D collaboration; China pharma; milestone payments; pharmaceutical industry

Bristol Myers Squibb Commits Up to $11B+ in Major BioNTech Solid Tumor Bispecific Antibody Deal

2 months ago talkbio0Tagged Antibodies, Bispecific, BioNTech, BNT327, Immunotherapy for cancer, milestone payments, Myers, Partnership, PD-L1, Solid Neoplasm, squibb, Vascular Endothelial Growth Factor A

Bristol Myers Squibb; BioNTech; BNT327; bispecific antibody; solid tumors; PD-L1; VEGF-A; cancer immunotherapy; partnership; milestone payments

RegenXBio Secures Up to $250 Million by Monetizing Royalties from Zolgensma and Two Gene Therapies

2 months ago talkbio0Tagged gene therapy, HealthCare Royalty, milestone payments, non-dilutive financing, Regenxbio, RGX-111, RGX-121, royalty monetization, Zolgensma

RegenXBio; Zolgensma; gene therapy; royalty monetization; HealthCare Royalty; RGX-121; RGX-111; non-dilutive financing; biotech; milestone payments

Novartis Invests $1 Billion in PTC Therapeutics’ Huntington’s Disease Program

8 months ago talkbio0Tagged Collaboration, factor IX, global license agreement, Huntington 's disease, milestone payments, Novartis, Phase 2 drug

Novartis, PTC Therapeutics, Huntington’s disease, Phase 2 drug, global license agreement, collaboration, upfront payment, milestone payments.

Sangamo Secures $50M Upfront in Neurodegenerative Pact with Roche’s Genentech

12 months ago talkbio0Tagged biobucks, genentech, milestone payments, Neurodegenerative, Roche (company), Sangamo

Sangamo, Roche, Genentech, neurodegenerative, biotech, licensing deal, milestone payments, biobucks

AstraZeneca Acquires Pinetree’s EGFR Degrader for $45 Million Upfront

12 months ago talkbio0Tagged AstraZeneca, Cancer Therapeutic Procedure, Epidermal Growth Factor Receptor, licensing agreement, milestone payments, molecular glues, Neoplasms, Pinetree, Protein Degradation, Metabolic, protein degrader, royalties

AstraZeneca, Pinetree Therapeutics, EGFR degrader, protein degrader, oncology, licensing agreement, milestone payments, royalties, targeted protein degradation, molecular glues, cancer treatment

Biotech Roundup: Compugen, Nxera Milestone Payments; Insmed Seeks $650M Offering

1 year ago talkbio0Tagged AstraZeneca, Bio, BMS, Breyanzi, Burning Mouth Syndrome, Celcuity, Compugen, K-ras Oncogene, luteolin-7-O-diglucuronide 4'-O-glucuronosyltransferase activity, milestone payments, Nordisk, Novartis, Nxera, United States Food and Drug Administration

Compugen, Nxera, milestone payments, Insmed, $650M offering, biotech, pharmaceuticals, Celcuity, Weave Bio, AstraZeneca, Novo Nordisk Foundation, FDA, LDT rule, BMS, Breyanzi, KRAS drug, Novartis